PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Oncoprotein C-MYC is overexpressed in human metastatic melanomas and melanoma-derived cells where it is required for the suppression of oncogene-induced senescence (OIS). The genetic events that maintain high levels of C-MYC in melanoma cells and their role in OIS are unknown. Here we report that C-MYC in cells from several randomly chosen melanoma lines was upregulated at the protein level, and largely because of the increased protein stability. Of all known regulators of C-MYC stability, levels of B56α subunit of the PP2A tumor suppressor complex were substantially suppressed in all human melanoma cells compared with normal melanocytes. Accordingly, immunohistochemical analysis revealed that the lowest and the highest amounts of PP2A-B56α were predominantly detected in metastatic melanoma tissues and in primary melanomas from patients with good clinical outcome, respectively. Importantly, PP2A-B56α overexpression suppressed C-MYC in melanoma cells and induced OIS, whereas depletion of PP2A-B56α in normal human melanocytes upregulated C-MYC protein levels and suppressed BRAFV600E- and, less efficiently, NRASQ61R-induced senescence. Our data reveal a mechanism of C-MYC overexpression in melanoma cells and identify a functional role for PP2A-B56α in OIS of melanocytic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 2×
“One of the best examples of naturally occurring OIS in humans is the nevus, a benign aggregation of non-proliferative melanocytes that often harbor activating mutations in BRAF, NRAS or HRAS genes (Pollock et al., 2003; Michaloglou et al., 2005; Gray-Schopfer et al., 2007).”
BackgroundSelf-citationHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 4×
“Intriguingly, activating mutations in the same genes have been detected in several types of malignant melanomas but at lower frequencies (Pollock et al., 2003; Curtin et al., 2005; Maldonado et al., 2003), indicating that malignant melanomas that often originate from nevi must have developed…”
BackgroundInfluentialMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 2×
“One of the best examples of naturally occurring OIS in humans is the nevus, a benign aggregation of non-proliferative melanocytes that often harbor activating mutations in BRAF, NRAS or HRAS genes (Pollock et al., 2003; Michaloglou et al., 2005; Gray-Schopfer et al., 2007).”
BackgroundCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 2×
“Other proteins regulating C-MYC stability include: CIP2A, a C-MYC-interacting protein that specifically inhibits PP2A activity against C-MYC (Junttila et al., 2007); USP28, a deubiquitinating enzymes that antagonizes FBW7 and promotes C-MYC stability (Popov et al., 2007) and TRUSS, a receptor for…”
BackgroundSelf-citationDeterminants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664 · cited 2×
“…mutations in the same genes have been detected in several types of malignant melanomas but at lower frequencies (Pollock et al., 2003; Curtin et al., 2005; Maldonado et al., 2003), indicating that malignant melanomas that often originate from nevi must have developed mechanisms that circumvent OIS.”
BackgroundParameters behind “Nonparametric” Statistics: Kendall's tau, Somers’ D and Median Differences
Newson, R. (2002) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0200200103 · Cited by 394
Tumor suppressors and oncogenes in cellular senescence
Bringold, F., & Serrano, M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00083-8 · Cited by 379
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
Denoyelle, C., Abou-Rjaily, G., Bezrookove, V., Verhaegen, M., Johnson, T. M., Fullen, D. R., Pointer, J. N., Gruber, S. B., Su, L. D., Nikiforov, M. A., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1471 · Cited by 349 · cited 10×
“Lentiviral constructs and infection Lentiviral infection protocols and vectors containing control shRNA, C-MYC shRNA, cDNAs of BRAFV600E, NRASQ61R and HRASG12V were described previously (Denoyelle et al., 2006; Arnold and Sears, 2006).”
BackgroundMethodInfluentialSelf-citation
Cited by
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
Self-citationProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“6 suppresses C-MYC in melanoma cells and induces oncogene-induced senescence, whereas depletion of B56α in normal human melanocytes upregulates C-MYC protein levels and Ser62 phosphorylation, and suppresses BRAF(V600E)- and, less efficiently, NRAS(Q61R)induced senescence (67).”
Background
Metadata
- Authors
- Mannava, S., Omilian, A. R., Wawrzyniak, J. A., Fink, E. E., Zhuang, D., Miecznikowski, J. C., Marshall, J. R., Soengas, M. S., Sears, R. C., Morrison, C. D., & Nikiforov, M. A.
- Venue
- Oncogene
- Published
- 2011-08-08
- Volume
- 31
- Issue
- 12
- Pages
- 1484-1492
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1971345156
- Cited by
- 42
- References
- 15
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells. https://app.cochat.ai/papers/10.1038/onc.2011.339
- The paper
- Mannava, S., Omilian, A. R., Wawrzyniak, J. A., Fink, E. E., Zhuang, D., Miecznikowski, J. C., Marshall, J. R., Soengas, M. S., Sears, R. C., Morrison, C. D., & Nikiforov, M. A. (2012). PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. https://doi.org/10.1038/onc.2011.339
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.